These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30367253)

  • 1. Designer Benzodiazepines: Another Class of New Psychoactive Substances.
    Moosmann B; Auwärter V
    Handb Exp Pharmacol; 2018; 252():383-410. PubMed ID: 30367253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
    Orsolini L; Corkery JM; Chiappini S; Guirguis A; Vento A; De Berardis D; Papanti D; Schifano F
    Curr Neuropharmacol; 2020; 18(9):809-837. PubMed ID: 31933443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam.
    Moosmann B; Bisel P; Franz F; Huppertz LM; Auwärter V
    J Mass Spectrom; 2016 Nov; 51(11):1080-1089. PubMed ID: 27535017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expanding world of new psychoactive substances-designer benzodiazepines.
    Zawilska JB; Wojcieszak J
    Neurotoxicology; 2019 Jul; 73():8-16. PubMed ID: 30802466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer benzodiazepines' pharmacological effects and potencies: How to find the information.
    El Balkhi S; Monchaud C; Herault F; Géniaux H; Saint-Marcoux F
    J Psychopharmacol; 2020 Sep; 34(9):1021-1029. PubMed ID: 31971477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
    Carpenter JE; Murray BP; Dunkley C; Kazzi ZN; Gittinger MH
    Clin Toxicol (Phila); 2019 Apr; 57(4):282-286. PubMed ID: 30430874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood concentrations of new designer benzodiazepines in forensic cases.
    Høiseth G; Tuv SS; Karinen R
    Forensic Sci Int; 2016 Nov; 268():35-38. PubMed ID: 27685473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The blood-to-plasma ratio and predicted GABA
    Manchester KR; Waters L; Haider S; Maskell PD
    Forensic Toxicol; 2022 Jul; 40(2):349-356. PubMed ID: 36454409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases.
    Pettersson Bergstrand M; Richter LHJ; Maurer HH; Wagmann L; Meyer MR
    Drug Test Anal; 2019 Jan; 11(1):45-50. PubMed ID: 29996009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Landscape of Designer Drugs.
    Kacinko SL; Papsun DM
    Methods Mol Biol; 2019; 1872():129-135. PubMed ID: 30350286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK.
    Abouchedid R; Gilks T; Dargan PI; Archer JRH; Wood DM
    J Med Toxicol; 2018 Jun; 14(2):134-143. PubMed ID: 29671244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step?
    Moustafa RE; Tarbah F; Saeed HS; Sharif SI
    Crit Rev Toxicol; 2021 Mar; 51(3):249-263. PubMed ID: 34038656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.
    Moosmann B; Bisel P; Auwärter V
    Drug Test Anal; 2014; 6(7-8):757-63. PubMed ID: 24604775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Development and Validation of a Novel Designer Benzodiazepines Panel by LC-MS-MS.
    Mastrovito RA; Papsun DM; Logan BK
    J Anal Toxicol; 2021 May; 45(5):423-428. PubMed ID: 33476376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer.
    El Balkhi S; Chaslot M; Picard N; Dulaurent S; Delage M; Mathieu O; Saint-Marcoux F
    Int J Legal Med; 2017 Jul; 131(4):979-988. PubMed ID: 28160051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of prescribed and designer benzodiazepines and metabolites in influent wastewater.
    Bade R; Ghetia M; White JM; Gerber C
    Anal Methods; 2020 Jul; 12(28):3637-3644. PubMed ID: 32701083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
    Bäckberg M; Pettersson Bergstrand M; Beck O; Helander A
    Clin Toxicol (Phila); 2019 Mar; 57(3):203-212. PubMed ID: 30348014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?
    Greenblatt DJ
    Clin Pharmacol Ther; 2019 Dec; 106(6):1175-1176. PubMed ID: 31441050
    [No Abstract]   [Full Text] [Related]  

  • 20. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.
    Brunetti P; Giorgetti R; Tagliabracci A; Huestis MA; Busardò FP
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34208284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.